Suggested remit: To appraise the clinical and cost effectiveness of finerenone within its marketing authorisation for treating heart failure with preserved or mildly reduced ejection fraction.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6514
Provisional Schedule
- Committee meeting: 1:
- 08 April 2026
- Expected publication:
- 04 June 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Bayer (finerenone)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Arrhythmia Alliance
- Atrial Fibrillation Association
- Blood Pressure UK
- Cardiac Risk in the Young (CRY)
- Cardiomyopathy UK
- Cardiovascular Care Partnership
- Circulation Foundation
- Heart Valve Voice
- Network of Sikh Organisations
- Pumping Marvellous Foundation
- Somerville Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- British and Irish Hypertension Society
- British Association for Nursing in Cardiovascular Care
- British Cardiovascular Society
- British Geriatrics Society
- British Heart Foundation
- British Heart Rhythm Society
- British Nuclear Cardiology Society
- British Society for Heart Failure
- British Society of Cardiovascular Imaging
- National Heart and Lung Institute
- Primary Care Cardiovascular Society
- Royal College of Emergency Medicine
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Cardiological Science & Technology
- Society for Vascular Nurses
- Society for Vascular Technology
- UK Clinical Pharmacy Association
- Vascular Society of Great Britain and Ireland
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Accord Healthcare (furosemide)
- ADVANZ Pharma (furosemide)
- AS Kalceks (furosemide)
- AstraZeneca (dapagliflozin)
- Baxter Healthcare (furosemide)
- Boehringer Ingelheim (empagliflozin)
- Hameln Pharmaceuticals (furosemide)
- Ipca Laboratories UK (furosemide)
- Mylan (bumetanide, torasemide)
- Pinewood Healthcare (furosemide)
- Rosemont Pharmaceuticals (bumetanide, furosemide)
- Thame Laboratories (furosemide)
- Tillomed Laboratories (furosemide)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- British Society for Cardiovascular Research
- Cardiac and Cardiology Research Dept, Barts
- Cochrane Heart, Stroke and Circulation Group
- European Council for Cardiovascular Research
- Genomics England
- Heart Research UK
- MRC Clinical Trials Unit
- National Centre for Cardiovascular Preventions and Outcomes
- National Institute for Health Research
- Wellcome Trust
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 August 2025 | Invitation to participate |
| 29 April 2025 - 29 May 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6514 |
| 29 April 2025 | In progress. Scoping commencing |
| 16 April 2025 | Referral |
| 14 November 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual